[go: up one dir, main page]

NO20074295L - Substituerte gamma lactamer som terapeutiske midler - Google Patents

Substituerte gamma lactamer som terapeutiske midler

Info

Publication number
NO20074295L
NO20074295L NO20074295A NO20074295A NO20074295L NO 20074295 L NO20074295 L NO 20074295L NO 20074295 A NO20074295 A NO 20074295A NO 20074295 A NO20074295 A NO 20074295A NO 20074295 L NO20074295 L NO 20074295L
Authority
NO
Norway
Prior art keywords
therapeutic agents
substituted gamma
gamma lactams
lactams
substituted
Prior art date
Application number
NO20074295A
Other languages
English (en)
Other versions
NO341339B1 (no
Inventor
David W Old
Danny T Dinh
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NO20074295L publication Critical patent/NO20074295L/no
Publication of NO341339B1 publication Critical patent/NO341339B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En forbindelse omfattende eller et farmasøytisk akseptabelt salt, prodroge eller en metabolitt derav er beskrevet her. Y, A og B er som beskrevet her. Metoder, preparater og medikamenter relatert til disse forbindelser er også beskrevet.
NO20074295A 2005-03-10 2007-08-22 Substituerte gamma laktamer, sammensetninger omfattende slike samt anvendelse av slike i medisinsk behandling NO341339B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66074805P 2005-03-10 2005-03-10
PCT/US2006/007797 WO2006098918A2 (en) 2005-03-10 2006-03-06 Substituted gamma lactams as therapeutic agents

Publications (2)

Publication Number Publication Date
NO20074295L true NO20074295L (no) 2007-12-07
NO341339B1 NO341339B1 (no) 2017-10-16

Family

ID=36579663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074295A NO341339B1 (no) 2005-03-10 2007-08-22 Substituerte gamma laktamer, sammensetninger omfattende slike samt anvendelse av slike i medisinsk behandling

Country Status (21)

Country Link
US (4) US7476747B2 (no)
EP (1) EP1856042B1 (no)
JP (2) JP5197354B2 (no)
KR (1) KR101276449B1 (no)
CN (2) CN105520941B (no)
AR (1) AR053162A1 (no)
AU (1) AU2006223514A1 (no)
BR (1) BRPI0609021A2 (no)
CA (1) CA2599425C (no)
DK (1) DK1856042T3 (no)
ES (1) ES2388929T3 (no)
HK (2) HK1116168A1 (no)
IL (1) IL185363A (no)
MX (1) MX2007010818A (no)
NO (1) NO341339B1 (no)
NZ (1) NZ560691A (no)
PL (2) PL384090A1 (no)
RU (1) RU2412933C2 (no)
TW (1) TWI386391B (no)
WO (1) WO2006098918A2 (no)
ZA (1) ZA200706852B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
US7476747B2 (en) * 2005-03-10 2009-01-13 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP1996546B1 (en) * 2006-03-20 2014-11-26 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
US7553860B2 (en) * 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
BRPI0716742A2 (pt) * 2006-08-11 2015-03-24 Allergan Inc Lactamas terapêuticas
BRPI0715974A2 (pt) * 2006-08-23 2014-09-16 Allergan Inc Tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados.
AU2008210559B2 (en) * 2007-01-31 2014-03-06 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US8377984B2 (en) 2008-01-29 2013-02-19 Allergan, Inc. Substituted gamma lactams as therapeutic agents
WO2008100809A1 (en) 2007-02-15 2008-08-21 Allergan, Inc. Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US8198315B2 (en) * 2007-05-23 2012-06-12 Allergan, Inc. Therapeutic substituted cyclic lactams
US7781465B2 (en) * 2007-08-21 2010-08-24 Allergan, Inc. Therapeutic oxazolidinones and thiazolidinones
US20090062361A1 (en) * 2007-08-30 2009-03-05 Allergan, Inc. Therapeutic hydantoins
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US7956055B2 (en) 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2721749A1 (en) * 2008-04-16 2009-10-22 Allergan, Inc. Combination therapy for glaucoma
US7879854B2 (en) * 2008-04-24 2011-02-01 Allergan, Inc. Substituted gamma lactams as therapeutic agents
BRPI0911347A2 (pt) * 2008-04-24 2018-03-20 Allergan Inc gama lactamas substituídas como agentes terapêuticos
EP2285782A2 (en) * 2008-05-09 2011-02-23 Allergan, Inc. Therapeutic n-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives
US7985765B2 (en) 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
WO2012024376A1 (en) * 2010-08-17 2012-02-23 Allergan, Inc. Ep2 or ep4 agonists for treating corneal haze
US8697057B2 (en) * 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012024072A1 (en) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8741281B2 (en) * 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012119059A1 (en) * 2011-03-03 2012-09-07 Allergan, Inc. Non-aqueous silicone-based ophthalmic formulations
US20130345149A1 (en) * 2011-03-03 2013-12-26 Allergan, Inc. Silicone-based ophthalmic formulations
KR102221534B1 (ko) * 2012-08-21 2021-02-26 알레간 인코포레이티드 치환된 감마 락탐의 합성을 위한 공정
US20140142042A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Skin wound healing and scar reduction with prostaglandin ep4 agonist combinations
MY177958A (en) 2013-10-31 2020-09-28 Allergan Inc Prostamide-containing intraocular implants and methods of use thereof
CA2962766A1 (en) * 2014-10-02 2016-04-07 Allergan, Inc. Ester prodrugs of gamma-lactams and their use
RU2568603C1 (ru) * 2015-01-15 2015-11-20 Федеральное агентство научных организаций (ФАНО России) Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Производные простагландина, обладающие противовоспалительной и анальгезирующей активностью

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
RU2288913C2 (ru) * 2001-07-16 2006-12-10 Ф.Хоффманн-Ля Рош Аг Аналоги простагландинов, способ их получения и фармацевтическая композиция, обладающая селективной агонистической активностью в отношении рецептора ep4
BR0213911A (pt) * 2001-11-05 2004-09-28 Allergan Inc Análogos de Èmega-cicloalquil 17-heteroaril prostaglandina e2 como agonistas do receptor ep2
EP1481976B1 (en) * 2002-03-05 2012-11-07 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7419999B2 (en) * 2002-06-10 2008-09-02 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
WO2004037813A1 (en) * 2002-10-25 2004-05-06 Merck Frosst Canada & Co. Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7476747B2 (en) * 2005-03-10 2009-01-13 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents

Also Published As

Publication number Publication date
IL185363A (en) 2012-03-29
IL185363A0 (en) 2008-02-09
EP1856042B1 (en) 2012-06-27
CA2599425C (en) 2013-04-30
US7473702B2 (en) 2009-01-06
JP2013032374A (ja) 2013-02-14
AR053162A1 (es) 2007-04-25
RU2007133581A (ru) 2009-04-20
KR101276449B1 (ko) 2013-06-20
CN101137622A (zh) 2008-03-05
WO2006098918A3 (en) 2006-11-23
TW200714583A (en) 2007-04-16
NO341339B1 (no) 2017-10-16
NZ560691A (en) 2011-03-31
RU2412933C2 (ru) 2011-02-27
WO2006098918B1 (en) 2006-12-28
JP5197354B2 (ja) 2013-05-15
HK1223851A1 (zh) 2017-08-11
MX2007010818A (es) 2007-11-12
ZA200706852B (en) 2008-09-25
CN105520941A (zh) 2016-04-27
WO2006098918A2 (en) 2006-09-21
ES2388929T3 (es) 2012-10-19
CA2599425A1 (en) 2006-09-21
PL384090A1 (pl) 2008-06-23
JP5762379B2 (ja) 2015-08-12
KR20070110920A (ko) 2007-11-20
US20070265330A1 (en) 2007-11-15
DK1856042T3 (da) 2012-09-17
AU2006223514A1 (en) 2006-09-21
CN105520941B (zh) 2020-05-01
TWI386391B (zh) 2013-02-21
US20110275692A1 (en) 2011-11-10
JP2008533011A (ja) 2008-08-21
BRPI0609021A2 (pt) 2010-01-12
US7973071B2 (en) 2011-07-05
HK1116168A1 (en) 2008-12-19
US20090233980A1 (en) 2009-09-17
EP1856042A2 (en) 2007-11-21
PL1856042T3 (pl) 2012-11-30
US20070287742A1 (en) 2007-12-13
US7476747B2 (en) 2009-01-13

Similar Documents

Publication Publication Date Title
NO20074295L (no) Substituerte gamma lactamer som terapeutiske midler
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
DE60334678D1 (de) Antikörper enthaltende pharmazeutische lösungen
RS53895B1 (en) ATP-BINDING CASSETTE TRANSPORT MODULATORS
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
DK1863812T3 (da) Dipeptidylpeptidase-IV-inhiberende forbindelser, fremgangsmåder til fremstilling af de samme og farmaceutiske sammensætninger indeholdende de samme som aktive midler
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
DK1599478T3 (da) Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
EA200600620A1 (ru) Набор для ингаляции с ингаляционным порошком, содержащим тиотропий
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
ECSP088296A (es) Compuestos terapéuticos
NO20065904L (no) Terapeutiske forbindelser
NO20075918L (no) Substituerte pyrrolo-pyridiner, forbindelser inneholdende disse, fremgangsmate for deres fremstilling og anvendelse derav
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
NO20044322L (no) Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
BRPI0716643A2 (pt) amidas terapêuticas e compostos relacionados
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
EP1900368A4 (en) TABLET WITH A SPIRIT OF SOLUBLE ACTIVE SUBSTANCE
NO20055631L (no) Doseringsform inneholdende pantoprazol som aktiv ingrediens

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees